<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>MEDANTA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">MEDANTA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="global-health-limited" class="section level1">
<h1>Global Health Limited</h1>
<p><a href="/reports01/index/industry/rp-Hospital.html">Hospital</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDANTA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="medanta-global-health-limited-investment-analysis-summary" class="section level9">
<p class="heading"><strong>MEDANTA (Global Health Limited) ‚Äì Investment Analysis Summary</strong></p>
<p><strong>Scrip Code:</strong> 543654 | <strong>Symbol:</strong> MEDANTA | <strong>Industry:</strong> Healthcare ‚Äì Hospitals &amp; Healthcare Services<br />
<strong>CIN:</strong> L85110DL2004PLC128319 | <strong>Headquarters:</strong> Gurgaon, India<br />
<strong>Listing Regulated by:</strong> SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</p>
<hr />
</div>
<div id="market-position-business-overview" class="section level6">
<h6><strong>1. Market Position &amp; Business Overview</strong></h6>
<ul>
<li><strong>Founder &amp; Leadership:</strong> Dr.¬†Naresh Trehan (Padma Bhushan awardee), currently Chairman &amp; Managing Director.</li>
<li><strong>Brand:</strong> Operates under the <strong>‚ÄúMedanta‚Äù brand</strong>, recognized as one of India‚Äôs leading <strong>multi-specialty tertiary and quaternary care providers</strong>.</li>
<li><strong>Operational Presence:</strong>
<ul>
<li>6 <strong>existing hospitals</strong> (Gurgaon, Indore, Ranchi, Lucknow, Patna, <strong>Noida</strong>)<br />
</li>
<li>3,435 <strong>installed beds</strong> as of September 30, 2025<br />
</li>
<li>Services across <strong>30+ specialties</strong> including Oncology, Cardiology, Neurosciences, GI, etc.</li>
</ul></li>
<li><strong>Upcoming Projects:</strong> 4 new hospitals in <strong>Mumbai, Pitampura (Delhi), South Delhi, and Guwahati</strong>.</li>
</ul>
<hr />
</div>
<div id="tailwinds-positive-growth-drivers" class="section level6">
<h6><strong>2. Tailwinds (Positive Growth Drivers)</strong></h6>
<div id="strategic-capacity-expansion-geographic-reach" class="section level9">
<p class="heading">‚úÖ <strong>1. Strategic Capacity Expansion &amp; Geographic Reach</strong></p>
<ul>
<li><strong>Noida Hospital Inauguration (November 27, 2025):</strong>
<ul>
<li>550-bed state-of-the-art facility with <strong>130+ ICU beds, 16 OTs</strong>, and advanced tech (Da Vinci robotics, PET-CT, etc.)</li>
<li>Located in NCR, close to densely populated Western UP.</li>
<li>Inaugurated by UP CM <strong>Yogi Adityanath</strong>, indicating government support and enhanced public credibility.</li>
<li>Projected employment creation: <strong>5,000‚Äì7,000 jobs</strong>.</li>
</ul></li>
<li><strong>Guwahati Land Secured (October 24, 2025):</strong>
<ul>
<li>3.5 acres allocated by <strong>AIDCL on 60-year lease</strong>, with renewal option.</li>
<li>Fulfills long-term strategy to expand in <strong>Northeast India</strong>, a high-growth, underserved region.</li>
</ul></li>
<li><strong>Ranchi Hospital Expansion:</strong> Additional facility near existing one boosts local capacity.</li>
</ul>
<blockquote>
<p><strong>Impact:</strong> Strengthens Medanta‚Äôs presence in <strong>emerging tier-1/II markets</strong>, captures untapped demand, enhances brand equity.</p>
</blockquote>
<hr />
</div>
<div id="modern-infrastructure-technology-adoption" class="section level9">
<p class="heading">‚úÖ <strong>2. Modern Infrastructure &amp; Technology Adoption</strong></p>
<ul>
<li>Noida hospital features <strong>cutting-edge technology</strong>:
<ul>
<li>Robotic Surgery (Da Vinci XI)</li>
<li>Biplane Cath Lab</li>
<li>TruBeam Radiosurgery</li>
<li>O-Arm imaging, 3T MRI, 256-slice CT</li>
</ul></li>
<li>Enhances <strong>clinical excellence</strong>, attracts top talent, supports premium pricing and high patient inflow.</li>
</ul>
<blockquote>
<p><strong>Impact:</strong> Differentiates from competitors; enables complex procedures; improves outcomes and reputation.</p>
</blockquote>
<hr />
</div>
<div id="positive-financial-momentum-q2-fy26-sept-2025" class="section level9">
<p class="heading">‚úÖ <strong>3. Positive Financial Momentum (Q2 FY26: Sept 2025)</strong></p>
<p><em>(All figures unadjusted; standalone, in ‚Çπ Crores)</em></p>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26 (Sep ‚Äô25)</th>
<th>Q1 FY26 (Jun ‚Äô25)</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Revenue from Operations</td>
<td>‚Çπ9,264.28</td>
<td>‚Çπ8,821.56</td>
<td>+11.4%</td>
</tr>
<tr class="even">
<td>Total Income</td>
<td>‚Çπ9,492.28</td>
<td>‚Çπ9,052.95</td>
<td>+5.1%</td>
</tr>
<tr class="odd">
<td>Profit Before Tax (PBT)</td>
<td>‚Çπ1,850.47</td>
<td>‚Çπ1,982.46</td>
<td>+5.5% YoY</td>
</tr>
<tr class="even">
<td>Profit After Tax (PAT)</td>
<td>‚Çπ1,401.99</td>
<td>‚Çπ1,519.64</td>
<td>+9.3% YoY</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Note:</strong> Despite sequential drop in PBT due to <strong>exceptional reversals in Q1</strong>, YoY profitability has improved. PAT up <strong>9.3% YoY (‚Çπ1.4k Cr)</strong>.</p>
</blockquote>
<div id="key-highlights" class="section level12">
<p class="heading"><strong>Key Highlights:</strong></p>
<ul>
<li><strong>Strong Revenue Growth:</strong> Up <strong>11.4% YoY</strong>, driven by service expansion and operationalization of new facilities.</li>
<li><strong>Free Cash Flow Positive:</strong> Net cash from operations: <strong>‚Çπ2,614 Cr</strong> (6 months).</li>
<li><strong>Healthy Balance Sheet:</strong> Cash &amp; equivalents ~ <strong>‚Çπ4,500‚Äì7,200 Cr</strong>.</li>
<li><strong>Consolidated PAT (Holding + Subsidiaries):</strong> ‚Çπ1,584 Cr (Q2), <strong>+21% YoY</strong>, indicating leverage from amalgamation.</li>
</ul>
<hr />
</div>
</div>
<div id="strategic-amalgamation-consolidation" class="section level9">
<p class="heading">‚úÖ <strong>4. Strategic Amalgamation &amp; Consolidation</strong></p>
<ul>
<li><strong>Amalgamation of Medanta Holdings Pvt Ltd with GHL effective April 1, 2024</strong>, approved Feb 2025 by NCLT.</li>
<li>Compliant with <strong>Appendix C of Ind AS 103 (Business Combination under Common Control)</strong>.</li>
<li><strong>Impact:</strong> Restated comparables show <strong>higher revenue base</strong>, better margins, operational synergy.</li>
<li>Allows <strong>simplified structure</strong>, reduced legal overheads, and unified capital allocation.</li>
</ul>
<hr />
</div>
<div id="employee-incentivization-talent-retention" class="section level9">
<p class="heading">‚úÖ <strong>5. Employee Incentivization &amp; Talent Retention</strong></p>
<ul>
<li><strong>605,500 stock options granted</strong>, 183,000 shares allotted to <strong>GHL Employees Welfare Trust</strong>.</li>
<li>Employee share-based payment expense: <strong>‚Çπ171.4 Cr (H1 FY26)</strong> ‚Üí indicates long-term retention strategy.</li>
<li>Helps attract clinicians and staff, especially for <strong>new projects in Mumbai, Guwahati, Delhi</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6><strong>3. Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="11%" />
<col width="28%" />
<col width="59%" />
</colgroup>
<thead>
<tr class="header">
<th>Project</th>
<th>Status</th>
<th>Expected Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Mumbai (750 beds)</strong></td>
<td>Capacity increased from <strong>500 ‚Üí 750</strong>; <strong>‚Çπ1,530 Cr total cost</strong> (was ‚Çπ1,200 Cr).</td>
<td>Largest Medanta hub; taps high-income metro market; expected to become <strong>cash flow breakeven in 3‚Äì4 years</strong>.</td>
</tr>
<tr class="even">
<td><strong>Noida</strong></td>
<td><strong>Launched Nov 2025</strong></td>
<td>Immediate EBITDA contribution expected; leverages proximity to Delhi; strong catchment.</td>
</tr>
<tr class="odd">
<td><strong>Guwahati</strong></td>
<td>Land secured (Oct 2025); construction to start</td>
<td>Strategic entry into Northeast; long-term growth with <strong>limited competition</strong>.</td>
</tr>
<tr class="even">
<td><strong>Pitampura &amp; South Delhi</strong></td>
<td>Under planning</td>
<td>Enhances capital city footprint with high patient affordability.</td>
</tr>
</tbody>
</table>
<blockquote>
<p><strong>Pipeline:</strong> 4 upcoming projects ‚Üí potential <strong>~1,500‚Äì2,000 new beds</strong> ‚Üí <strong>~45% increase</strong> in capacity over next 4‚Äì5 years.</p>
</blockquote>
<div id="long-term-growth-catalysts" class="section level12">
<p class="heading">üìà Long-Term Growth Catalysts:</p>
<ul>
<li>Rising <strong>healthcare demand</strong> in semi-urban &amp; rural India.</li>
<li>Increasing <strong>health insurance penetration</strong>.</li>
<li>Government focus on <strong>public-private partnerships (PPP)</strong>.</li>
<li>Aging population &amp; <strong>rise in lifestyle diseases</strong>.</li>
<li><strong>Medical tourism potential</strong> with global-standard facilities.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges" class="section level6">
<h6><strong>4. Headwinds &amp; Challenges</strong></h6>
<div id="capex-intensity-leverage-risk" class="section level9">
<p class="heading">‚ö†Ô∏è <strong>1. Capex Intensity &amp; Leverage Risk</strong></p>
<ul>
<li><strong>Mumbai Project cost escalated</strong> from ‚Çπ1,200 Cr ‚Üí ‚Çπ1,530 Cr (+‚Çπ330 Cr).
<ul>
<li>Includes <strong>‚Çπ85 Cr for 30 staff residential flats</strong>.</li>
</ul></li>
<li>Total Mumbai investment now one of the largest corporate healthcare projects in India.</li>
<li><strong>Financing Mode:</strong> Mix of <strong>internal accruals and debt</strong>, increasing financial risk.</li>
<li>Consolidated borrowings: <strong>Non-current borrowings ~‚Çπ1,800 Cr</strong>, lease liabilities <strong>~‚Çπ3,900 Cr</strong> ‚Üí cautious for incremental debt.</li>
</ul>
<hr />
</div>
<div id="construction-execution-delays" class="section level9">
<p class="heading">‚ö†Ô∏è <strong>2. Construction &amp; Execution Delays</strong></p>
<ul>
<li>Mumbai, Guwahati, Delhi projects in <strong>pre-construction or early phase</strong>.</li>
<li>Subject to <strong>permitting, labor, supply chain disruptions</strong>, and project-level regulatory clearances.</li>
<li>Delays could defer ROI, impact investor sentiment.</li>
</ul>
<hr />
</div>
<div id="gradual-profitability-ramp-up" class="section level9">
<p class="heading">‚ö†Ô∏è <strong>3. Gradual Profitability Ramp-Up</strong></p>
<ul>
<li>New hospitals are <strong>not EBITDA positive initially</strong>; typically take 2‚Äì3 years to breakeven.</li>
<li>Noida, Guwahati, Mumbai may <strong>drag consolidated margins</strong> in short to medium term.</li>
<li>Requires sustained investment in marketing, staffing, and equipment.</li>
</ul>
<hr />
</div>
<div id="competitive-pressure" class="section level9">
<p class="heading">‚ö†Ô∏è <strong>4. Competitive Pressure</strong></p>
<ul>
<li>Increasing competition from:
<ul>
<li><strong>Apollo Hospitals</strong>, Fortis (now IHH), Max Healthcare, Narayana Health.</li>
<li>Regional players like <strong>AIIMS</strong> (in public sector), government schemes (ABPMJAY).</li>
</ul></li>
<li>Need to <strong>differentiate via service quality, digital integration, and innovation</strong>.</li>
</ul>
<hr />
</div>
</div>
<div id="key-risks" class="section level6">
<h6><strong>5. Key Risks</strong></h6>
<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr class="header">
<th>Risk Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Operational Risk</strong></td>
<td>Delay in commissioning new hospitals; execution bottlenecks; recruitment challenges for new facilities.</td>
</tr>
<tr class="even">
<td><strong>Financial Risk</strong></td>
<td>Rising Capex (Mumbai project); high lease liabilities; reliance on debt financing.</td>
</tr>
<tr class="odd">
<td><strong>Regulatory Risk</strong></td>
<td>Medical liability cases, pricing scrutiny, real estate compliance in Mumbai (FSI), stamp duty/legal precedents.</td>
</tr>
<tr class="even">
<td><strong>Clinical &amp; Reputation Risk</strong></td>
<td>Medical errors or adverse outcomes at new facilities could harm brand.</td>
</tr>
<tr class="odd">
<td><strong>Macro Risk</strong></td>
<td>Economic slowdown affecting elective procedure volumes; insurance reimbursement delays.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="summary-investment-thesis" class="section level6">
<h6><strong>6. Summary ‚Äì Investment Thesis</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="57%" />
</colgroup>
<thead>
<tr class="header">
<th>Aspect</th>
<th>Verdict</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>‚úÖ Tailwinds</strong></td>
<td>Strong brand, leading clinical network, tech edge, strategic expansion into underserved regions (NE, UP), successful Noida launch, favorable reimbursement trends.</td>
</tr>
<tr class="even">
<td><strong>üö© Headwinds</strong></td>
<td>High capex, delayed payback, project execution risks, incremental debt, lease liability burden.</td>
</tr>
<tr class="odd">
<td><strong>üìà Growth Prospects</strong></td>
<td><strong>Strong and structural</strong>: 4 major projects underway, <strong>750-bed Mumbai</strong> becoming a mega-hub, <strong>Noida &amp; Guwahati</strong> capturing underserved demand. Expected <strong>&gt;40% capacity growth in 5 years</strong>.</td>
</tr>
<tr class="even">
<td><strong>üìâ Risks</strong></td>
<td>Execution, financing, competition. But offset by Dr.¬†Trehan‚Äôs leadership, operational track record, and digital-first patient engagement.</td>
</tr>
<tr class="odd">
<td><strong>üéØ Overall Outlook</strong></td>
<td><strong>POSITIVE (Buy/Hold)</strong> ‚Äì Long-term buy-and-hold candidate with moderate volatility due to high project exposure. Attractive for investors seeking healthcare infrastructure play in India.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="key-metrics-snapshot-as-of-30-sept-2025-unaudited" class="section level6">
<h6><strong>7. Key Metrics Snapshot (as of 30 Sept 2025 ‚Äì Unaudited)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Amount (‚Çπ Crore)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue (Q2 FY26)</strong></td>
<td>9,264</td>
</tr>
<tr class="even">
<td><strong>Standalone PAT (Q2 FY26)</strong></td>
<td>1,402</td>
</tr>
<tr class="odd">
<td><strong>Consolidated PAT (Q2 FY26)</strong></td>
<td>1,584</td>
</tr>
<tr class="even">
<td><strong>Operational Beds</strong></td>
<td>3,435</td>
</tr>
<tr class="odd">
<td><strong>Cash &amp; Equivalents (Standalone)</strong></td>
<td>4,501 ‚Üí up to 7,234 by Sept</td>
</tr>
<tr class="even">
<td><strong>Mumbai Project Capex</strong></td>
<td>‚Çπ1,530 Cr (incl.¬†land &amp; staff housing)</td>
</tr>
<tr class="odd">
<td><strong>Upcoming Beds (Pipeline)</strong></td>
<td>~1,800+ (Mumbai: 750, others: ~1,000+)</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion" class="section level6">
<h6><strong>Conclusion</strong></h6>
<p><strong>Medanta (GHL)</strong> is at a <strong>transformative inflection point</strong>: - Transitioning from a <strong>regional premium player</strong> to a <strong>national healthcare powerhouse</strong>. - Strategic expansions in <strong>Noida, Mumbai, and Northeast</strong> position it well for long-term volume and revenue growth. - Strong financial discipline, <strong>healthy operating cash flows</strong>, and timely amalgamation enhance corporate governance. - While <strong>nearing-term margins may be pressured by expansion</strong>, the <strong>long-term growth runway is compelling</strong>.</p>
<blockquote>
<p><strong>Recommendation:</strong> <strong>Accumulate on dips</strong> for medium to long-term horizon. Monitor <strong>Q3 FY26 execution, Mumbai FSI progress, and capex discipline</strong>.</p>
</blockquote>
<hr />
<p><em>Note: All information sourced from Medanta‚Äôs disclosures to BSE/NSE under SEBI (LODR) Regulations, 2015, dated between May 2025 and December 2025.</em></p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
